Hypertension as a risk factor for diabetic neuropathy: A prospective study

Diabetes

Volumn 46, Issue 4, 1997, Pages 665-670

  Forrest, Kimberly Y Z ^a   Maser, Raelene E ^c   Pambianco, Georgia ^a   Becker, Dorothy J ^b   Orchard, Trevor J ^a,d  

^a GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF DELAWARE   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY HEIGHT; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE DURATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING;

EID: 0031000731     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.4.665     Document Type: Article

References (39)

1. Pirart J: Tight glycaemic control prevents diabetic complications. Acta Clinica Belgica 50:321-325, 1995
2. Pirart J: Diabetes mellitus and its degenerative complications. I. a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1:168-188, 1978
3. Pirart J: Diabetes mellitus and its degenerative complications. II. aprospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1:252-263, 1978
4. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
5. + - ATPase activity, metabolic control, and neuropathy in IDDM patients. Diabetes Care 19:564-568, 1996
6. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH: Prevalence of complications in IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39:1116-1124, 1990
7. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, Drash AL, Becker DJ, Kuller LH, Greene DA, Orchard TJ: Epidemiological correlates of diabetic neuropathy: report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 38:1456-1461, 1989
8. Christiansen JS: Cigarette smoking and prevalence of microanginopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes Care 1:146-149, 1978
9. Mitchell BD, Hawthorne VM, Vinik AI: Cigarette smoking and neuropathy in diabetic patients. Diabetes Care 13:434-437, 1990
10. Gadia MT, Natori N, Ramos LB, Ayyar DR, Skyler JS, Sosenko JM: Influence of height on quantitative sensory nerve conduction, and clinical indices of diabetic peripheral neuropathy. Diabetes Care 10:613-616, 1987
11. Sosenko JM, Boulton AJM, Gadia MT, Ward JD, Skyler JS: The association between symptomatic sensory neuropathy and body stature in diabetic patients. Diabetes Res Clin Pract 4:95-98, 1988
12. Hyllienmark L, Brismar T, Ludvigsson J: Subclinical nerve dysfunction in children and adolescents with IDDM. Diabetologia 38:685-692, 1995
13. Harris M, Eastman R, Cowie C: Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 16:1446-1452, 1993
14. Report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 11:592-597, 1988
15. American Diabetes Association: Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Diabetes Care 15 (Suppl. 3):1080-1107, 1992
16. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Ellis D, LaPorte RE, Kuller LH, Wolfson SK Jr, Drash AL: Factors associated with avoidance of severe complications after 25 years of IDDM: Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 13:741-747, 1990
17. The DCCT Research Group: Factors in development of diabetic neuropathy: baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). Diabetes 37:476-181, 1988
18. Maser RE, Nielsen VK, Bass EB, Manjoo Q, Dorman JS, Kelsey SF, Becker DJ, Orchard TJ: Measuring diabetic neuropathy: assessment and comparison of clinical examination and quantitative sensory testing. Diabetes Care 12:270-275, 1989
19. Arezzo JC: Quantitative Sensory Testing of Vibration Threshold Vibratron II: Rationale and Methods. Clifton, NJ, Physitemp Inst., 1993
20. Borhani NO, Kass EH, Langford HG, Payne GH, Remington RD, Stamler J: The hypertension detection and follow-up program. Prev Med 5:207-215, 1976
21. 2+ quantitaüon of high density lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem 24:900-904, 1978
22. National Institutes of Health, Department of Health, Education and Welfare: Lipid Research Clinics Program. Washington, D.C., U.S. Govt. Printing Office, 1975 (NIH publ. no. 75-628)
23. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. Clin Chem 20:470-475, 1974
24. Bucolo G, David H: Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19:476-482, 1973
25. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
26. Orchard TJ, CCSP Investigators: Validation of coronary heart disease mortality data: the community cardiovascular surveillance project P: 0 lot experience. Am Heart Assoc Cariovasc Dis Epidemiol Newslett 157:46, 1985
27. Orchard TJ, Strandness DE: Assessment of peripheral vascular disease in diabetes: report and recommendations of an international workshop sponsored by the AHA and ADA. Diabetes Care 16:1199-1209, 1993
28. Early Treatment of Diabetic Retinopathy Study Coordinating Center: Manual of Operations. Baltimore, MD, Univ of MD School of Medicine, 1980, p. 18
29. Lloyd CE, Becker D, Wolfson SK, Orchard TJ: Incidence of complications in IDDM: a survival analysis. Am J Epidemiol 143:431-441, 1996
30. Franklin GM, Shetterly SM, Cohen JA, Baxter J, Hamman RF: Risk factors for distal symmetric neuropathy in NJDDM: the San Luis Valley Diabetes Study. Diabetes Care 17:1172-1177, 1994
31. Knuiman MW, Welbom TA, McCann VJ, Stanton KG, Constable IJ: Prevalence of diabetic complications in relation to risk factors. Diabetes 35:1332-1339, 1986
32. Robinson LR, Stolov WC, Rubner DE, Wahl PW, Leonetti DL, Fujimoto WY: Height is an independent risk factor for neuropathy in diabetic men. Diabetes Res Clin Pract 16:97-102, 1992
33. Founds HW, Giordano D, Mitsuhashi T, Stitt A, Cerami A, Vlassara H, Bacala R: Tobacco smoke is a source of advanced glycaaon end products (AGEs): possible role in the accelerated vascular disease of smokers. Presented at the 1st Annual Meeting of the Molecular Medicine Society, May 3-6,1996, Washington, DC
34. +-ATPase activity in hypertensive patients. Clin Chim Acta 163:329-337, 1987
35. +-ATPase activity does not predict therapeutic response to calcium antagonists in essentia hypertension. Clin Chem 40:1532-1536, 1994
36. Shindo H, Thomas TP, Larkin DD, Karihaloo AK, Inada H, Onaya T, Stevens MJ, Greene DA: Modulation of basal nitric oxide-dependent cyclic-GMP production by ambient glucose, myoinositol, and protein kinase C in SH-SY5Y human neuroblastoma cells. J Clin Invest 97:736-745, 1996
37. Reja A, Tesfaye S, Harris ND, Ward JD: Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabetic Med 12:307-309, 1995
38. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ: Coronary artery disease in IDDM: gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol 16:720-726, 1996
39. Franklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF: Sensory neuropathy in non-insulin-dependent diabetes mellitus: the San Luis Valley Diabetes Study. Am J Epid 131:633-643, 1990